1-7 of 7
Sheel Patel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Free
Meghan Thompson, Constantine Tam, Kenneth Wu, Sheel Patel, Motohisa Takai, Patrick Phuong, Shelonitda Rose, Mark-David Levin, Talha Munir, Paolo Ghia, John Seymour
Journal: Blood
Blood (2025) 146 (Supplement 1): 5691.
https://doi.org/10.1182/blood-2025-5691
Published: 2025
Journal Articles

Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study

Free
Constantine Tam, Mary Ann Anderson, Masa Lasica, Emma Verner, Stephen Opat, Shuo Ma, Robert Weinkove, Raul Cordoba, Jacob Soumerai, Paolo Ghia, Sophie Leitch, David Westerman, Sheel Patel, Yiqian Fang, James Hilger, Remus Vezan, Chan Cheah
Journal: Blood
Blood (2025) 146 (Supplement 1): 3891.
https://doi.org/10.1182/blood-2025-3891
Published: 2025
Journal Articles

Zanubrutinib + obinutuzumab + sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL): Initial results from an ongoing phase 1/1b study, BGB-11417-101

Free
Jacob Soumerai, Stephen Opat, Chan Cheah, Mazyar Shadman, Emma Verner, Monica Tani, Marc Hoffmann, Lori Leslie, Shuo Ma, Yiqian Fang, Gabriel Man, Binghao Wu, Charity Henrich, Sheel Patel, Remus Vezan, Constantine Tam
Journal: Blood
Blood (2025) 146 (Supplement 1): 3890.
https://doi.org/10.1182/blood-2025-3890
Published: 2025
Journal Articles

MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: Initial results from an ongoing phase 1/1b study, BGB-11417-101

Free
Marc Hoffmann, Shuo Ma, Herbert Eradat, Constantine Tam, Masa Lasica, Paul Hampel, Emma Verner, Lori Leslie, Christopher D'Angelo, Jacob Soumerai, Mazyar Shadman, Chan Cheah, Monica Tani, Yiqian Fang, Binghao Wu, Gabriel Man, Sheel Patel, Remus Vezan, Stephen Opat
Journal: Blood
Blood (2025) 146 (Supplement 1): 793.
https://doi.org/10.1182/blood-2025-793
Published: 2025
Journal Articles

Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101

Free
Jacob D. Soumerai, Chan Y. Cheah, Mary Ann Anderson, Masa Lasica, Emma Verner, Stephen S. Opat, Shuo Ma, Robert Weinkove, Raul Cordoba, Paolo Ghia, Sophie Leitch, David Westerman, Sheel Patel, Yiqian Fang, Wei Ding, Haiyi Guo, Constantine S. Tam
Journal: Blood
Blood (2024) 144 (Supplement 1): 1012.
https://doi.org/10.1182/blood-2024-199175
Published: 2024
Journal Articles

Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose

Free
Hang Quach, Doug Sborov, Dickran Kazandjian, Andrew Spencer, Michael Low, Susan Bal, Natalie S. Callander, Huan Cheng, Sheel Patel, Rocco J. Crescenzo, Amit Agarwal, Binod Dhakal
Journal: Blood
Blood (2023) 142 (Supplement 1): 1011.
https://doi.org/10.1182/blood-2023-178735
Published: 2023
Journal Articles

Preliminary Safety of a Bcl-2 Inhibitor, Bgb-11417, in Patients with Relapsed/Refractory Multiple Myeloma Harboring t(11,14): A Non-Randomized, Open-Label, Phase 1b/2 Study

Free
Hang Quach, Rajeev Rajagopal, Andrew Spencer, Michael Low, Dickran Kazandjian, Rocco Crescenzo, Chenmu Du, Sheel Patel, Vaibhav Mundra, Huan Cheng, Binod Dhakal
Journal: Blood
Blood (2022) 140 (Supplement 1): 7269–7271.
https://doi.org/10.1182/blood-2022-169666
Published: 2022